Artivion, Inc. AORT
Set alert
At close · Oct 30
After hours · Oct 30, 4:01 PM ET
- YTD
- -50.49%
- 1 year
- -50.54%
- Open
- 23.62
- Prev close
- 23.44
- Mkt cap
- 1.10B
- Vol
- 627.38K
- Avg vol
- 624.75K
- EPS
- -0.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 21.85
- High
- 23.52
- Forward P/E
- 29.95
- Beta
- 1.22
- Short ratio
- 6.21
- Inst. own
- 96.46%
- Dividend
- 0.00
- Ex-div date
- Dec 8, 2015
- Earnings
- Nov 5, 2026
- 50-d avg
- 23.98
- 200-d avg
- 29.49
- 1y target
- 40.91
1D chart
Signals (35)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | 3:59 PM | 2 days ago |
| MACD: Buy Signal | 3:56 PM | 2 days ago |
| MACD: Sell Signal | 3:55 PM | 2 days ago |
| MACD: Buy Signal | 3:46 PM | 2 days ago |
| MACD: Sell Signal | 3:42 PM | 2 days ago |
| SMA: Bullish | 3:23 PM | 2 days ago |
| SMA: Bullish | 3:23 PM | 2 days ago |
| MACD: Buy Signal | 3:17 PM | 2 days ago |
| MACD: Sell Signal | 3:09 PM | 2 days ago |
| MACD: Buy Signal | 3:08 PM | 2 days ago |
| SMA: Bearish | 2:47 PM | 2 days ago |
| SMA: Bullish | 2:39 PM | 2 days ago |
| SMA: Bearish | 2:33 PM | 2 days ago |
| MACD: Sell Signal | 2:33 PM | 2 days ago |
| SMA: Bearish | 2:21 PM | 2 days ago |
| SMA: Bullish | 2:20 PM | 2 days ago |
| MACD: Buy Signal | 2:02 PM | 2 days ago |
| RSI: Oversold | 1:52 PM | 2 days ago |
| MACD: Sell Signal | 1:18 PM | 2 days ago |
| SMA: Bearish | 1:13 PM | 2 days ago |
| MACD: Buy Signal | 12:57 PM | 2 days ago |
| SMA: Bullish | 12:52 PM | 2 days ago |
| SMA: Bullish | 12:52 PM | 2 days ago |
| SMA: Bearish | 12:45 PM | 2 days ago |
| SMA: Bullish | 12:43 PM | 2 days ago |
| SMA: Bearish | 12:35 PM | 2 days ago |
| MACD: Sell Signal | 12:35 PM | 2 days ago |
| MACD: Buy Signal | 12:31 PM | 2 days ago |
| MACD: Sell Signal | 12:30 PM | 2 days ago |
| SMA: Bullish | 12:03 PM | 2 days ago |
| SMA: Bullish | 11:54 AM | 2 days ago |
| MACD: Buy Signal | 11:54 AM | 2 days ago |
| MACD: Sell Signal | 11:49 AM | 2 days ago |
| SMA: Bullish | 11:15 AM | 2 days ago |
| MACD: Buy Signal | 11:08 AM | 2 days ago |
Key statistics
- Market cap
- 1.09B
- Enterprise value
- 1.47B
- Trailing P/E
- 0.00
- Forward P/E
- 29.95
- PEG ratio
- 643.75
- Price / sales
- 2.32
- Price / book
- 2.45
- EPS (TTM)
- -0.07
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -0.67%
- Revenue (TTM)
- 471.47M
- Revenue growth
- 11.30%
- Free cash flow
- 13.10M
- Total cash
- 77.32M
- Total debt
- 407.97M
- Return on equity
- -0.73%
- Shares outstanding
- 48.76M
- Short % of float
- 9.21%
- 50-day average
- 23.98
- 200-day average
- 29.49
Analyst view
Consensus: strong buy
- Target (low)
- 31.00
- Target (mean)
- 40.91
- Target (high)
- 48.00
- Strong buy2
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.066.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.06125 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.0025 | -0.28 | -0.28 | -11,300.00% |
| May 7, 2026 | Mar 31, 2026 | 0.06 | 0.03 | -0.03 | -50.00% |
| Feb 12, 2026 | Dec 31, 2025 | 0.14 | 0.051 | -0.09 | -63.57% |
| Nov 6, 2025 | Sep 30, 2025 | 0.14 | 0.16 | +0.02 | +14.29% |
| Aug 7, 2025 | Jun 30, 2025 | 0.11 | 0.0303 | -0.08 | -72.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 20, 2026 | Jefferies | init | — | Buy |
| Aug 18, 2026 | Canaccord Genuity | main | Buy | Buy |
| Jul 20, 2026 | Needham | reit | Buy | Buy |
| Jun 16, 2026 | Canaccord Genuity | main | Buy | Buy |
| May 8, 2026 | Citizens | main | Market Outperform | Market Outperform |
| May 8, 2026 | Needham | main | Buy | Buy |
About Artivion, Inc.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- artivion.com
News
- Artivion to Participate in Upcoming Investor Conferences
- Jefferies Initiates Coverage On Artivion with Buy Rating, Announces Price Target of $31
- Transcript: Artivion Q2 2026 Earnings Conference Call
- Canaccord Genuity Maintains Buy on Artivion, Raises Price Target to $40
- Artivion Affirms FY2026 Sales Guidance of $480.000M-$496.000M vs $486.232M Est
- Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval
- Artivion Says FDA Approves Premarket Approval Application For AMDS Hybrid Prosthesis
- Crude Oil Gains 1%; Fluor Shares Plunge After Q1 Results
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Citizens Maintains Market Outperform on Artivion, Lowers Price Target to $48
Your note
Sign in to keep a note on AORT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ACKERMAN THOMAS F | Director | Stock Award(Grant) | May 17, 2026 | 157,472 |
| BERRY LANCE A | Chief Operating Officer | Sale | Aug 13, 2026 | 210,112 |
| BEVEVINO DANIEL J | Director | Stock Award(Grant) | May 17, 2026 | 157,637 |
| BULLOCK JAMES W | Director | Stock Award(Grant) | May 17, 2026 | 76,223 |
| BURBANK JEFFREY H | Director | Stock Award(Grant) | May 17, 2026 | 61,372 |
| DAVIS JOHN E | Officer | Sale | Mar 2, 2026 | 230,794 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.69% | 6,674,017 | 149.60M | Jun 29, 2026 |
| Nomura Asset Management International Inc | 6.53% | 3,184,974 | 71.39M | Jun 29, 2026 |
| Morgan Stanley | 5.25% | 2,557,961 | 57.34M | Jun 29, 2026 |
| Juniper Investment Company, LLC | 4.14% | 2,019,885 | 45.28M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.11% | 2,004,619 | 44.93M | Jun 29, 2026 |
| FMR, LLC | 4.03% | 1,963,471 | 44.01M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 2,901,339 | 65.03M | Sep 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 3.56% | 1,737,106 | 38.94M | May 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 1,463,340 | 32.80M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.42% | 1,180,717 | 26.47M | Sep 29, 2026 |
| Conestoga Funds-Conestoga Small Cap Fund | 1.97% | 962,620 | 21.58M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Value Fund | 1.25% | 610,573 | 13.69M | Jul 30, 2026 |